12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abilify aripiprazole regulatory update

EMA's CHMP issued a positive opinion to extend the indication for Otsuka's Abilify to include treatment of moderate to severe manic episodes in bipolar I disorder in adolescents ages >=13 years for up to 12 weeks. Abilify is approved in...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >